{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:18:38Z","timestamp":1753888718354,"version":"3.41.2"},"reference-count":34,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of liver disease in the US, while Rheumatoid arthritis (RA) affects a significant portion of the global population. In recent times, newer drugs have been developed to slow down the progression of RA, one of which is hydroxychloroquine (HCQ). Despite HCQ being linked to slowly progressive transaminitis, its role in the development of NASH remains unclear. Our research fills this gap by examining the prevalence and risk factors of developing NASH in patients with RA on HCQ.  Methods: This retrospective cohort study analyzed 619,350 adult patients diagnosed with RA. Data were sourced from a multicenter database covering over 360 hospitals across 26 healthcare systems in the US from 1999 to September 2022, excluding pregnant individuals. Multivariate regression analysis assessed the risk of NASH, adjusting for confounders including smoking history, male gender, dyslipidemia, hypertension, type 2 diabetes mellitus, obesity, and hydroxychloroquine use. Statistical significance was set at P&lt;0.05, with analyses conducted using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria, 2008).  Results: In a cohort of 79.4 million individuals, 619,350 non-pregnant subjects had rheumatoid arthritis, with 3,080 diagnosed with NASH, while 616,270 did not. Patients with NASH displayed a higher prevalence of smoking history, hyperlipidemia, hypertension, type 2 diabetes mellitus, obesity, and HCQ use. Multivariate regression analysis identified increased NASH risk in smokers (OR: 1.24; 95%CI: 1.14-1.36), males (OR: 0.88; 95%CI: 0.81-0.96), individuals with dyslipidemia (OR: 1.34; 95%CI: 1.21-1.47), hypertension (OR: 1.11; 95%CI: 1.00-1.27), type 2 diabetes mellitus (OR: 3.24; 95%CI: 2.98-3.54), obesity (OR: 3.59; 95%CI: 3.31-3.89), and hydroxychloroquine use (OR: 1.79; 95%CI: 1.65-1.94).  Conclusion: RA patients on HCQ showed an increased prevalence and odds of developing NASH, even after adjusting for common confounding factors. This indicates that HCQ may play a role in the development of hepatic steatosis and fibrosis. Clinicians should consider this association to prevent advanced liver disease. Future research should focus on optimal screening for early detection and enhancing patient outcomes.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612024-100","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:37:52Z","timestamp":1743770272000},"source":"Crossref","is-referenced-by-count":0,"title":["PREVALENCE AND RISK FACTORS ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON HYDROXYCHLOROQUINE: A POPULATION-BASED STUDY"],"prefix":"10.1590","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4661-1443","authenticated-orcid":false,"given":"Antoine","family":"BOUSTANY","sequence":"first","affiliation":[{"name":"University of Florida College of Medicine,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5060-3131","authenticated-orcid":false,"given":"Somtochukwu","family":"ONWUZO","sequence":"additional","affiliation":[{"name":"Allegheny Health Network,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1845-5989","authenticated-orcid":false,"given":"Adejoke","family":"JOHNSON","sequence":"additional","affiliation":[{"name":"North Central Bronx Hospital,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1111-9447","authenticated-orcid":false,"given":"David","family":"FARHAT","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4609-2157","authenticated-orcid":false,"given":"Mimi","family":"NAJJAR","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-3043","authenticated-orcid":false,"given":"Hadi Khaled Abou","family":"ZEID","sequence":"additional","affiliation":[{"name":"University of Balamand,  Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5674-3424","authenticated-orcid":false,"given":"Chidera N","family":"ONWUZO","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-9807","authenticated-orcid":false,"given":"Mohamad-Noor","family":"ABU-HAMMOUR","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-3294","authenticated-orcid":false,"given":"Rashid","family":"ABDEL-RAZEQ","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-4895","authenticated-orcid":false,"given":"Islam","family":"MOHAMED","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2503-4947","authenticated-orcid":false,"given":"Barish","family":"EREN","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-6625","authenticated-orcid":false,"given":"Imad","family":"ASAAD","sequence":"additional","affiliation":[{"name":"Firelands Health,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra S","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang DQ","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","article-title":"2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis","volume":"20","author":"Le MH","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng ML","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances","volume":"113","author":"Noureddin M","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi Z","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","series-title":"StatPearls","volume-title":"Nonalcoholic Steatohepatitis (NASH)","author":"Sharma B","year":"2024"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","volume":"18","author":"Wang TY","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic Fatty Liver Disease 2020: The State of the Disease","volume":"158","author":"Cotter TG","year":"2020","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini G","year":"2003","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.3390\/ijerph18105227","article-title":"Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors","volume":"18","author":"Juanola O","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5604\/16652681.1171749","article-title":"Drug-induced fatty liver disease: An overview of pathogenesis and management","volume":"14","author":"Satapathy SK","year":"2015","journal-title":"Annals of Hepatology"},{"key":"ref15","series-title":"Elsevier eBooks","first-page":"501","volume-title":"Rheumatoid arthritis","author":"Alivernini S","year":"2019"},{"series-title":"The IBM Explorys Platform: liberate your healthcare data","key":"ref16"},{"year":"2021","series-title":"Systematized Nomenclature of Medicine- Clinical Terms (SNOMED CT)","key":"ref17"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: RxNorm at 6 years","volume":"18","author":"Nelson SJ","year":"2011","journal-title":"J Am Med Inform Assoc"},{"key":"ref19","first-page":"1","article-title":"Epidemiology and risk of colorectal cancer in patients with a history of Helicobacter pylori infection: a population-based study","volume":"36","author":"Boustany A","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"ref20","first-page":"6","article-title":"Increased Risk of Central Retinal Vein Occlusion in Patients with Inflammatory Bowel Disease: A Population-Based Study","author":"Boustany A","year":"2022","journal-title":"J Ophtalmol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3389\/fphar.2019.00855","article-title":"Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism","volume":"10","author":"Qiao X","year":"2019","journal-title":"Front Pharmacol"},{"year":"2020","series-title":"Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis - ACR Meeting Abstracts","key":"ref22"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0961203314561667","article-title":"Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report","volume":"24","author":"Abdel Galil SM","year":"2015","journal-title":"Lupus"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s10067-006-0218-1","article-title":"Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease","volume":"26","author":"Giner Galva\u00f1 V","year":"2007","journal-title":"Clin Rheumatol"},{"year":"2020","series-title":"Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis - ACR Meeting Abstracts","key":"ref25"},{"year":"2024","series-title":"Chloroquine and hydroxychloroquine toxicity","author":"Stokkermans TJ","key":"ref26"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4269\/ajtmh.20-0276","article-title":"Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19","volume":"102","author":"Falc\u00e3o MB","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.15171\/apb.2016.076","article-title":"Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats","volume":"6","author":"Niknahad H","year":"2016","journal-title":"Adv Pharm Bull"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/antiox11112217","article-title":"Role of Oxidative Stress and Lipid Peroxidation in the Pathophysiology of NAFLD","volume":"11","author":"Mart\u00edn-Fern\u00e1ndez M","year":"2022","journal-title":"Antioxidants"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.31083\/j.fbl2807137","article-title":"Hydroxychloroquine Toxicity in the Vital Organs of the Body: In Vivo Study","volume":"28","author":"Alruw~aili M","year":"2023","journal-title":"Front Biosci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/liv.13150","article-title":"The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease","volume":"36","author":"Kazankov K","year":"2016","journal-title":"Liver Int"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/j.1572-0241.2006.00680.x","article-title":"Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution","volume":"101","author":"Malaguarnera L","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref33","first-page":"1287","article-title":"Hydroxychloroquine Effects on THP-1 Macrophage Cholesterol Handling: Cell Culture Studies Corresponding to the TARGET Cardiovascular","volume":"58","author":"Ahmed S","year":"2022","journal-title":"Trial. Medicina (Kaunas)"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam M","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Preval\u00eancia e fatores de risco associados \u00e0 esteatohepatite n\u00e3o alco\u00f3lica em pacientes com artrite reumatoide em uso de hidroxicloroquina: um estudo de base populacional"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032025000100501&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:39:09Z","timestamp":1743770349000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032025000100501&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"alternative-id":["S0004-28032025000100501"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612024-100","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e24100"}}